U.K. Ophthalmology Spin-Out Raises £8m For DME Programs
This article was originally published in The Pink Sheet Daily
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.
You may also be interested in...
Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.
Shrinking Funding Rounds For European Biotechs Are No Surprise, But Series A Rounds Look Healthy, If Few
Nearly half (48%) of the 27 fundraisings by private European biotech companies so far this year have been for sums totaling $10 million or less, according to Elsevier's "Strategic Transactions" database. That's a significant increase over the same period in 2010, when less than 30% of financings were sub-$10 million.